Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
24.02
-0.27 (-1.11%)
At close: Aug 24, 2026, 4:00 PM EDT
23.78
-0.24 (-1.00%)
After-hours: Aug 24, 2026, 7:40 PM EDT
Viridian Therapeutics Employees
Viridian Therapeutics had 252 employees as of December 31, 2025. The number of employees increased by 109 or 76.22% compared to the previous year.
Employees
252
Change (1Y)
109
Growth (1Y)
76.22%
Revenue / Employee
$282,250
Profits / Employee
-$1,325,524
Market Cap
2.72B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 252 | 109 | 76.22% | 252 | 0 |
| Dec 31, 2024 | 143 | 49 | 52.13% | 143 | 0 |
| Dec 31, 2023 | 94 | 8 | 9.30% | 94 | 0 |
| Dec 31, 2022 | 86 | 36 | 72.00% | 86 | 0 |
| Dec 31, 2021 | 50 | 23 | 85.19% | 50 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Ultragenyx Pharmaceutical | 1,371 |
| Beam Therapeutics | 540 |
| Ocular Therapeutix | 325 |
| Nurix Therapeutics | 317 |
| Disc Medicine | 165 |
| Precigen | 160 |
| Pharvaris | 148 |
VRDN News
- 17 days ago - Viridian Therapeutics price target raised to $39 from $38 at Truist - TheFly
- 17 days ago - Viridian Therapeutics price target raised to $36 from $35 at RBC Capital - TheFly
- 18 days ago - Viridian Therapeutics reports EPS ($1.05), consensus ($1.03) - TheFly
- 18 days ago - Viridian Therapeutics sees cash runway through profitability - TheFly
- 18 days ago - Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results - Business Wire
- 18 days ago - Viridian Therapeutics Earnings release: Q2 2026 - Filings
- 18 days ago - Viridian Therapeutics Slides: Q2 2026 - Filings
- 18 days ago - Viridian Therapeutics Quarterly report: Q2 2026 - Filings